BFRI vs. CALC, GRCE, GBIO, ALXO, BCAB, EGRX, DARE, GDTC, TPST, and OKUR
Should you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include CalciMedica (CALC), Grace Therapeutics (GRCE), Generation Bio (GBIO), ALX Oncology (ALXO), BioAtla (BCAB), Eagle Pharmaceuticals (EGRX), Daré Bioscience (DARE), CytoMed Therapeutics (GDTC), Tempest Therapeutics (TPST), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical products" industry.
Biofrontera vs.
Biofrontera (NASDAQ:BFRI) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.
In the previous week, Biofrontera had 16 more articles in the media than CalciMedica. MarketBeat recorded 18 mentions for Biofrontera and 2 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.60 beat Biofrontera's score of -0.09 indicating that CalciMedica is being referred to more favorably in the news media.
10.1% of Biofrontera shares are owned by institutional investors. 1.2% of Biofrontera shares are owned by insiders. Comparatively, 41.5% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Biofrontera has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
Biofrontera has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
CalciMedica received 9 more outperform votes than Biofrontera when rated by MarketBeat users. Likewise, 94.74% of users gave CalciMedica an outperform vote while only 69.23% of users gave Biofrontera an outperform vote.
CalciMedica has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. CalciMedica's return on equity of -164.24% beat Biofrontera's return on equity.
Biofrontera currently has a consensus target price of $2.75, suggesting a potential upside of 325.63%. CalciMedica has a consensus target price of $18.00, suggesting a potential upside of 928.57%. Given CalciMedica's higher probable upside, analysts plainly believe CalciMedica is more favorable than Biofrontera.
Summary
CalciMedica beats Biofrontera on 10 of the 16 factors compared between the two stocks.
Get Biofrontera News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biofrontera Competitors List
Related Companies and Tools
This page (NASDAQ:BFRI) was last updated on 5/22/2025 by MarketBeat.com Staff
